Navigation Links
Premier Research Appoints Melissa Jones as Vice President, International Business Development
Date:9/11/2007

PHILADELPHIA, Sept. 11 /PRNewswire-FirstCall/ -- Premier Research Group plc (AIM: PRG) announces the appointment of Melissa Jones as Vice President, International Business Development. Ms. Jones will be responsible for leading the International Business Development group.

Ms. Jones previously held a senior business development position within Kendle International leading a Global Key Account group. She has over 11 years experience within business development in the CRO sector with such companies as Innovex, Quintiles, MDS Pharma Services, and Kendle International. Ms. Jones began her career working within data management for Innovex progressing to team management where she was also responsible for the insourcing of data managers within the pharmaceutical sector. Ms. Jones has a BSc Honors degree in Biology from the University of Portsmouth.

Commenting on Ms. Jones' appointment, Peter Malamis, President, Global Corporate Development, said, "We are delighted to be able to welcome Melissa into the organization in this important role both as a leader for our International Sales group and as a member of our senior management team. Melissa brings to the company extensive business development and management experience and will make an immediate and significant impact on the continued successful growth of the company."

About Premier Research

Premier Research is a leading solutions-driven CRO leveraging our commitment to therapeutic focus and scientific expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leader in clinical research for Analgesia, CNS, Infectious Disease, and Oncology and have a wealth of experience in medical device and pediatric research. Premier Research has 29 offices and operates in more than 30 countries across Europe and North America. Premier Research employs more than 850 clinical professionals dedicated first and foremost to fulfilling each client's requirements in a timely, accurate and cost-effective manner. This includes a strong international network of monitors and project management professionals combined with regulatory, data management, statistical, scientific and medical experts, and staff at well-established network of dedicated clinical sites.


'/>"/>
SOURCE Premier Research Group plc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
2. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
3. Control Your siRNA Research
4. Getting Started with MicroRNA Research
5. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
6. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
7. Research Organics
8. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
9. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
10. Research Tools for Analysis of ZAP-70
11. Technical Specifications Accelerating Your Research with the BD FACSCanto High Throughput Sampler Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):